Press Releases

Date Title and Summary
Toggle Summary Akcea and Ionis Announce Filing of New Drug Submission for Volanesorsen to Health Canada
Health Canada grants priority review for volanesorsen NDS filing Volanesorsen could be the first approved treatment for patients with FCS CAMBRIDGE, Mass. and CARLSBAD, Calif., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc.
Toggle Summary Akcea and Ionis Announce Positive Results from Pivotal Study of Volanesorsen in Patients with Familial Chylomicronemia Syndrome (FCS)
Toggle Summary Akcea and Ionis Announce Submission of Marketing Authorization Application for Volanesorsen to the European Medicines Agency
CAMBRIDGE, Mass. and CARLSBAD, Calif. , July 27, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA) and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that a marketing authorization application (MAA) has been submitted to the European Medicines Agency (EMA) for volanesorsen
Toggle Summary Akcea and Ionis Announce Submission of New Drug Application for Volanesorsen to the U.S. FDA
<p>CAMBRIDGE, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today
Toggle Summary Akcea Announces Publication in The New England Journal of Medicine of Data with AKCEA-ANGPTL3-L Rx Showing Favorable Cardiometabolic Effects
Toggle Summary Akcea Initiates Phase 2 Study of AKCEA-APO(a)-L Rx in Patients with High Lp(a) and Cardiovascular Disease
Toggle Summary Akcea Reports Financial Results and Highlights for Second Quarter 2017
Toggle Summary Akcea Therapeutics Announces Appointment of Edward Fitzgerald to Board of Directors
Toggle Summary Akcea Therapeutics Announces Closing of Initial Public Offering
CAMBRIDGE, Mass. , July 19, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. today announced the closing of its initial public offering of 17,968,750 shares common stock at a public offering price of $8.00 per share, including 2,343,750 shares of common stock issued upon full exercise by the
Toggle Summary Akcea Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass. , July 13, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. today announced the pricing of its initial public offering of 15,625,000 shares common stock at a public offering price of $8.00 per share, for gross proceeds of $125.0 million before underwriting discounts and commissions